<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>Gout — One‑Page Quick Reference Algorithm (NICE CKS 2023)</title>
  <meta name="description" content="Clean, modern one‑page reference for diagnosing and managing gout in primary care, based on NICE CKS 2023." />
  <style>
    :root{
      --bg: #0f172a;          /* slate-900 */
      --bg-soft:#111827;      /* gray-900 */
      --card:#0b1226;         /* deep slate */
      --card-2:#0a0f1f;       
      --text:#e5e7eb;         /* gray-200 */
      --muted:#9ca3af;        /* gray-400 */
      --accent:#22d3ee;       /* cyan-400 */
      --accent-2:#60a5fa;     /* blue-400 */
      --ok:#34d399;           /* emerald-400 */
      --warn:#fbbf24;         /* amber-400 */
      --danger:#f87171;       /* red-400 */
      --shadow: 0 12px 24px rgba(0,0,0,.35), inset 0 1px 0 rgba(255,255,255,.03);
      --radius: 18px;
    }
    *{box-sizing:border-box}
    html,body{height:100%}
    body{
      margin:0; font-family: ui-sans-serif, system-ui, -apple-system, Segoe UI, Roboto, "Helvetica Neue", Arial, "Noto Sans", "Apple Color Emoji", "Segoe UI Emoji";
      color:var(--text); background: radial-gradient(1200px 600px at 10% 0%,#1e293b 0%, var(--bg) 50%), linear-gradient(180deg,#0b1020, #0b0f1d 35%, #0b0f1d 100%);
      line-height:1.55; letter-spacing:.2px;
    }
    a{color:var(--accent)}
    /* Header / Hero */
    header{
      position:relative; padding:72px 20px 40px; overflow:hidden;
      background: radial-gradient(800px 400px at 80% -10%, rgba(34,211,238,.10), transparent 60%),
                  radial-gradient(1000px 500px at 10% -15%, rgba(96,165,250,.10), transparent 65%);
    }
    .container{max-width:1100px; margin:0 auto}
    .hero{display:flex; gap:28px; align-items:flex-end; flex-wrap:wrap}
    .badge{display:inline-flex; align-items:center; gap:8px; padding:6px 10px; border-radius:999px; font-size:12px; letter-spacing:.4px; text-transform:uppercase; color:#082f33; background:linear-gradient(180deg,#67e8f9,#22d3ee); font-weight:700}
    .title{font-size: clamp(28px, 4.2vw, 44px); margin:.35em 0 .15em; font-weight:800; letter-spacing:.2px}
    .subtitle{color:var(--muted); max-width:800px}

    /* Top actions / toc */
    .toolbar{position:sticky; top:0; z-index:30; backdrop-filter:saturate(180%) blur(10px); background:rgba(11,15,29,.65); border-bottom:1px solid rgba(255,255,255,.06)}
    .toolbar .inner{display:flex; gap:14px; align-items:center; justify-content:space-between; padding:10px 18px}
    .toc{display:flex; flex-wrap:wrap; gap:8px}
    .toc a{font-size:13px; text-decoration:none; color:var(--text); opacity:.9; padding:8px 12px; border-radius:12px; border:1px solid rgba(255,255,255,.08); background:rgba(255,255,255,.03)}
    .toc a:hover{border-color:rgba(255,255,255,.2)}
    .actions{display:flex; gap:10px}
    .btn{appearance:none; border:1px solid rgba(255,255,255,.1); background:linear-gradient(180deg, rgba(255,255,255,.06), rgba(255,255,255,.02)); color:var(--text); padding:8px 12px; border-radius:12px; font-weight:600; cursor:pointer}
    .btn:hover{border-color:rgba(255,255,255,.25)}

    /* Grid */
    main{padding:36px 20px 80px}
    .grid{display:grid; grid-template-columns: repeat(12, 1fr); gap:18px}
    .card{grid-column: span 12; background:linear-gradient(180deg, rgba(255,255,255,.04), rgba(255,255,255,.02)); border:1px solid rgba(255,255,255,.08); border-radius:var(--radius); box-shadow:var(--shadow); padding:20px 20px}
    @media(min-width:880px){
      .col-6{grid-column: span 6}
      .col-4{grid-column: span 4}
      .col-8{grid-column: span 8}
    }

    /* Card head */
    .card h2{margin:0 0 12px; font-size: clamp(18px, 2.4vw, 24px)}
    .eyebrow{display:inline-flex; align-items:center; gap:10px; font-size:12px; color:var(--muted); text-transform:uppercase; letter-spacing:.45px}
    .icon{width:22px; height:22px; display:inline-block}

    /* Lists */
    ul{margin:8px 0 0 0; padding-left:18px}
    .bullet li{margin:6px 0}
    .tight li{margin:2px 0}
    .note{font-size:13px; color:var(--muted)}

    /* Pills */
    .pill{display:inline-flex; align-items:center; gap:8px; padding:6px 10px; border-radius:999px; font-size:12px; font-weight:700; letter-spacing:.3px}
    .pill.ok{color:#03281d; background:linear-gradient(180deg,#6ee7b7,#34d399)}
    .pill.warn{color:#2e2503; background:linear-gradient(180deg,#fde68a,#fbbf24)}
    .pill.danger{color:#30090a; background:linear-gradient(180deg,#fca5a5,#f87171)}

    /* Callouts */
    .callout{display:flex; gap:14px; align-items:flex-start; border:1px dashed rgba(255,255,255,.16); padding:12px 12px; border-radius:12px; background:rgba(255,255,255,.03); margin-top:10px}
    .callout .lead{font-weight:700}

    /* Definition list style */
    dl{display:grid; grid-template-columns: 1fr 2.2fr; gap:8px 14px; margin:0}
    dt{color:var(--muted)}
    dd{margin:0}

    /* Foot */
    footer{color:var(--muted); font-size:12px; text-align:center; padding:24px}

    /* Print styles */
    @media print{
      body{background:#fff; color:#000}
      header{background:#fff; padding:0 0 8px 0}
      .toolbar{position:static; backdrop-filter:none; background:#fff; border:0}
      .toc a,.btn{border:1px solid #000}
      .card{box-shadow:none; border:1px solid #000}
      .badge{background:#000; color:#fff}
      a{color:#000; text-decoration:underline}
      .pill.ok{background:#d1fae5}
      .pill.warn{background:#fef3c7}
      .pill.danger{background:#fee2e2}
    }
  </style>
</head>
<body>
  <header>
    <div class="container">
      <span class="badge">NICE CKS &nbsp;•&nbsp; Gout</span>
      <div class="hero">
        <div>
          <h1 class="title">Gout — One‑Page Quick Reference Algorithm</h1>
          <p class="subtitle">Rapid, consultation‑ready summary for adults (≥16y): diagnosis, acute flare management, treat‑to‑target ULT, monitoring, and referral cues. Built from CKS (last revised June 2023).</p>
        </div>
      </div>
    </div>
  </header>

  <div class="toolbar">
    <div class="container inner">
      <nav class="toc">
        <a href="#diagnosis">Diagnosis</a>
        <a href="#acute">Acute Flare</a>
        <a href="#followup">Post‑Flare</a>
        <a href="#ult">ULT: When & Targets</a>
        <a href="#practical">ULT Practicalities</a>
        <a href="#prophylaxis">Flare Prophylaxis</a>
        <a href="#monitoring">Monitoring</a>
        <a href="#referral">Referral</a>
        <a href="#patient">Patient Messages</a>
        <a href="#rx">Prescribing Quick Notes</a>
      </nav>
      <div class="actions">
        <button class="btn" onclick="window.print()">Print / Save PDF</button>
      </div>
    </div>
  </div>

  <main class="container">
    <section id="diagnosis" class="grid">
      <article class="card col-6">
        <div class="eyebrow"><svg class="icon" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M12 21c4.97 0 9-4.03 9-9S16.97 3 12 3 3 7.03 3 12s4.03 9 9 9Z" stroke="currentColor" opacity=".5"/><path d="M8.5 12.5h7M12 8.5v8" stroke="currentColor"/></svg> Step 1</div>
        <h2>Diagnosis / Rule‑out</h2>
        <ul class="bullet">
          <li>Sudden severe monoarthritis (often 1st MTP) with erythema, warmth, swelling. Consider other joints (midfoot, ankle, knee, hand/wrist/elbow).</li>
          <li><strong>Septic arthritis?</strong> If systemically unwell or hot swollen joint → urgent aspiration/culture via local pathway.</li>
          <li>Measure <strong>serum urate</strong>: ≥ <strong>360 µmol/L</strong> (≥6 mg/dL) supports diagnosis. If &lt;360 but high suspicion, repeat 2–4 weeks post‑flare.</li>
          <li>Crystals (if available) confirm; imaging (US/DECT/X‑ray) if uncertainty.</li>
        </ul>
        <p class="note">Gout may occur with normal urate; hyperuricaemia may exist without gout.</p>
      </article>

      <article id="acute" class="card col-6">
        <div class="eyebrow"><svg class="icon" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M20 7 9.5 17.5 4 12" stroke="currentColor"/></svg> Step 2</div>
        <h2>Acute Flare — Treat ASAP</h2>
        <ul class="bullet">
          <li><strong>NSAID</strong> (e.g., naproxen, full dose) <em>+ consider PPI</em>.</li>
          <li><strong>Colchicine</strong>.</li>
          <li><strong>Prednisolone</strong> 30–35 mg OD × 3–5 days.</li>
          <li><strong>Intra‑articular / IM steroid</strong> if NSAID/colchicine not tolerated or ineffective.</li>
          <li>Combine therapies if suboptimal response; add <strong>paracetamol</strong> as adjunct.</li>
        </ul>
        <div class="callout"><span class="pill.ok">Tips</span><div>
          <div class="lead">Supportive:</div>
          rest, elevate, cool environment, ice packs. <strong>Continue ULT</strong> if already on it. Avoid aspirin. IL‑1 inhibitors only if NSAIDs/colchicine/steroids are contraindicated, not tolerated, or ineffective (specialist advice).
        </div></div>
      </article>
    </section>

    <section id="followup" class="grid">
      <article class="card col-6">
        <div class="eyebrow"><svg class="icon" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><circle cx="12" cy="12" r="9" stroke="currentColor" opacity=".5"/><path d="M12 8v5l3 2" stroke="currentColor"/></svg> Step 3</div>
        <h2>4–6 Weeks Post‑Flare</h2>
        <ul class="bullet">
          <li>Check <strong>serum urate</strong>.</li>
          <li>Educate: nature of gout, progression without ULT, options for flares.</li>
          <li>Assess lifestyle + comorbidities (CVD risk, CKD, obesity, alcohol). Offer CKD testing (eGFR<sub>creatinine</sub>, ACR).</li>
          <li>Review meds; discuss long‑term <strong>ULT</strong> risks/benefits.</li>
        </ul>
      </article>

      <article id="ult" class="card col-6">
        <div class="eyebrow"><svg class="icon" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M4 12h16M12 4v16" stroke="currentColor"/></svg> Step 4</div>
        <h2>When to Start ULT & Targets</h2>
        <dl>
          <dt>Offer ULT (treat‑to‑target) if</dt>
          <dd>≥2 flares/yr; CKD G3–G5; tophi; chronic gouty arthritis; diuretic therapy.</dd>
          <dt>Discuss ULT with others</dt>
          <dd>After first or subsequent flare.</dd>
          <dt>Serum urate targets</dt>
          <dd><strong>&lt;360 µmol/L</strong> (&lt;6 mg/dL); consider <strong>&lt;300 µmol/L</strong> (&lt;5 mg/dL) if tophi/chronic arthritis or frequent flares.</dd>
        </dl>
      </article>
    </section>

    <section id="practical" class="grid">
      <article class="card col-6">
        <div class="eyebrow"><svg class="icon" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M5 12h14" stroke="currentColor"/><path d="M12 5v14" stroke="currentColor" opacity=".5"/></svg> Step 5</div>
        <h2>ULT Practicalities</h2>
        <ul class="bullet">
          <li><strong>Timing:</strong> start ≥2–4 weeks after flare settles (can start during frequent flares).</li>
          <li><strong>Agent:</strong> <u>Allopurinol first‑line</u> (esp. with major CVD). Febuxostat if needed/contraindication to allopurinol.</li>
          <li><strong>Titration:</strong> check urate monthly and up‑titrate to target as tolerated.</li>
          <li><strong>Screening:</strong> LFTs before febuxostat; consider <em>HLA‑B*58:01</em> testing in high‑prevalence groups before allopurinol.</li>
        </ul>
      </article>

      <article id="prophylaxis" class="card col-6">
        <div class="eyebrow"><svg class="icon" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><rect x="4" y="4" width="16" height="16" rx="3" stroke="currentColor"/></svg> Step 6</div>
        <h2>Flare Prophylaxis During ULT Start/Titration</h2>
        <ul class="bullet">
          <li><strong>Colchicine</strong> preferred.</li>
          <li>If contraindicated/not tolerated/ineffective → <strong>NSAID ± PPI</strong> or <strong>short corticosteroid</strong>.</li>
          <li>Do <em>not</em> use IL‑1 inhibitor for prophylaxis unless other options unsuitable (specialist advice).</li>
        </ul>
      </article>
    </section>

    <section id="monitoring" class="grid">
      <article class="card col-6">
        <div class="eyebrow"><svg class="icon" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M3 12h18" stroke="currentColor"/><circle cx="12" cy="12" r="8" stroke="currentColor" opacity=".5"/></svg> Step 7</div>
        <h2>Monitoring</h2>
        <ul class="bullet">
          <li>Urate monthly until target, then <strong>annually</strong>.</li>
          <li>Check renal function regularly; screen CVD risks & comorbidities at least annually; offer CKD testing (eGFR, ACR).</li>
          <li>Watch for <strong>allopurinol hypersensitivity</strong> (esp. on initiation).</li>
          <li><strong>Febuxostat:</strong> monitor LFTs periodically by clinical judgement.</li>
        </ul>
      </article>

      <article id="referral" class="card col-6">
        <div class="eyebrow"><svg class="icon" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M6 12h12" stroke="currentColor"/><path d="M12 6v12" stroke="currentColor"/></svg> Step 8</div>
        <h2>Referral Triggers</h2>
        <ul class="bullet">
          <li class="pill danger" style="margin:4px 0">Suspected septic arthritis → <strong>immediate</strong> referral</li>
          <li>Uncertain diagnosis; poor response/intolerance/contraindications.</li>
          <li>CKD G3b–G5 or transplant.</li>
          <li>Need for joint injection where expertise/facilities lacking.</li>
          <li>Pregnancy; age &lt;30; suspicion of systemic rheumatic disease; complications; high risk of drug AEs.</li>
        </ul>
      </article>
    </section>

    <section id="patient" class="grid">
      <article class="card col-12">
        <div class="eyebrow"><svg class="icon" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M12 2v20M2 12h20" stroke="currentColor"/></svg> Step 9</div>
        <h2>Key Patient Messages</h2>
        <ul class="bullet">
          <li>Gout is lifelong; untreated hyperuricaemia forms crystals and drives progression.</li>
          <li>ULT prevents flares, shrinks tophi, and averts joint damage when sustained to target.</li>
          <li>Healthy balanced diet; manage weight and alcohol. Continue ULT during flares and treat flares promptly.</li>
        </ul>
      </article>
    </section>

    <section id="rx" class="grid">
      <article class="card col-8">
        <div class="eyebrow"><svg class="icon" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><path d="M7 12h10" stroke="currentColor"/><rect x="4" y="4" width="16" height="16" rx="4" stroke="currentColor" opacity=".5"/></svg> Prescribing Quick Notes</div>
        <h2>Selected Dosing & Safety Reminders</h2>
        <ul class="bullet">
          <li><strong>Colchicine (acute):</strong> 500 µg 2–4× daily until pain relief (max 6 mg/course; don’t repeat within 3 days). Reduce dose or extend interval if eGFR 10–50; contraindicated if eGFR &lt;10. Narrow therapeutic index; toxic in overdose.</li>
          <li><strong>Allopurinol (ULT):</strong> start ≤100 mg daily (after food); titrate by 100 mg every 4 weeks to urate target (typical 100–600 mg/day; up to 700–900 mg/day severe—divide doses &gt;300 mg). Use lower doses in elderly, hepatic/renal impairment; consider HLA‑B*58:01 in high‑risk ancestry.</li>
          <li><strong>Febuxostat (ULT):</strong> consider if allopurinol contraindicated/not tolerated; check LFTs before start and monitor as needed; use caution in major cardiovascular disease—prefer allopurinol first‑line in CVD.</li>
          <li><strong>NSAIDs:</strong> use full anti‑inflammatory dose; consider PPI for gastric protection; avoid aspirin for gout.</li>
          <li><strong>Corticosteroids:</strong> short oral course for flares; intra‑articular helpful for monoarthritis when feasible.</li>
        </ul>
        <p class="note">Always check BNF/eMC for full contraindications, interactions, and adverse effects.</p>
      </article>
      <article class="card col-4">
        <div class="eyebrow"><svg class="icon" viewBox="0 0 24 24" fill="none" xmlns="http://www.w3.org/2000/svg"><circle cx="12" cy="12" r="9" stroke="currentColor"/></svg> At‑a‑Glance Thresholds</div>
        <h2>Numbers to Remember</h2>
        <ul class="tight">
          <li><strong>Diagnosis:</strong> urate ≥ 360 µmol/L (≥6 mg/dL)</li>
          <li><strong>Targets:</strong> &lt; 360 µmol/L; consider &lt; 300 µmol/L if tophi/chronic or frequent flares</li>
          <li><strong>Follow‑up:</strong> 4–6 weeks post‑flare</li>
          <li><strong>Pred:</strong> 30–35 mg OD × 3–5 days</li>
        </ul>
      </article>
    </section>

    <footer>
      Built for quick in‑clinic use. Print‑friendly. This page condenses the NICE Clinical Knowledge Summaries (CKS) guidance on gout for adults (last revised June 2023).
    </footer>
  </main>
</body>
</html>
